Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;54(1):557-9.
doi: 10.1128/AAC.00912-09. Epub 2009 Nov 16.

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance

Catharine C Bulik  1 , Henry Christensen, David P Nicolau
Affiliations

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance

Catharine C Bulik et al. Antimicrob Agents Chemother. 2010 Jan.

Abstract

We describe the activity of a novel cephalosporin, CXA-101 (FR26 4205), against a panel of highly resistant Pseudomonas aeruginosa isolates collected from U.S. hospitals. CXA-101 demonstrated increased potency against this population of resistant isolates, with activity that is 4- to 10-fold higher than that of comparator agents in each phenotypic category. The addition of tazobactam did not improve its activity. CXA-101 appears to be a promising addition to the category of antipseudomonal beta-lactams.

PubMed Disclaimer

References

    1. Castanheira, M., R. N. Jones, and D. M. Livermore. 2009. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa and other non-fermentative bacilli, and Aeromonas spp. Diagn. Microbiol. Infect. Dis. 63:426-433. - PubMed
    1. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI publication M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Crandon, J. L., J. L. Kuti, and D. P. Nicolau. 2009. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann. Pharmacother. 43:220-227. - PubMed
    1. Eagye, K. J., J. L. Kuti, C. A. Sutherland, H. Christensen, and D. P. Nicolau. Potency of commonly-used hospital-based antibiotics against non-urine clinical isolates of Escherichia coli and Pseudomonas aeruginosa at 40 U.S. hospitals. Clin. Ther., in press. - PubMed
    1. Flamm, R. K., M. K. Weaver, C. Thornsberry, M. E. Jones, J. A. Karlowsky, and D. F. Sahm. 2004. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother. 48:2431-2436. - PMC - PubMed

Publication types